NASDAQ:CODX Co-Diagnostics (CODX) Stock Price, News & Analysis $1.29 -0.02 (-1.53%) (As of 04:26 PM ET) Add Compare Share Share Today's Range$1.28▼$1.3550-Day Range$1.02▼$1.7552-Week Range$0.98▼$2.23Volume61,198 shsAverage Volume150,523 shsMarket Capitalization$40.35 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Co-Diagnostics alerts: Email Address Co-Diagnostics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside16.3% Upside$1.50 Price TargetShort InterestHealthy1.05% of Shares Sold ShortDividend StrengthN/ASustainability-1.10Upright™ Environmental ScoreNews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.23) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.29 out of 5 starsMedical Sector311th out of 927 stocksSurgical & Medical Instruments Industry40th out of 101 stocks 2.0 Analyst's Opinion Consensus RatingCo-Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 1 research reports in the past 90 days.Read more about Co-Diagnostics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.05% of the outstanding shares of Co-Diagnostics have been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Co-Diagnostics has recently increased by 8.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCo-Diagnostics has received a 67.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Infectious disease diagnostics systems", and "PCR machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Co-Diagnostics is -1.10. Previous Next 3.0 News and Social Media Coverage News SentimentCo-Diagnostics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Co-Diagnostics this week, compared to 1 article on an average week.Search Interest6 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 14.99% of the stock of Co-Diagnostics is held by institutions.Read more about Co-Diagnostics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Co-Diagnostics are expected to grow in the coming year, from ($1.23) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Co-Diagnostics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTrillion Dollar Blockchain Shift Could Trigger THIS CoinIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW About Co-Diagnostics Stock (NASDAQ:CODX)Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Read More CODX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CODX Stock News HeadlinesSeptember 5, 2024 | finance.yahoo.comCo-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO TestAugust 26, 2024 | uk.finance.yahoo.comCODX Sep 2024 1.000 call (CODX240906C00001000)September 16, 2024 | Crypto 101 Media (Ad)Trillion Dollar Blockchain Shift Could Trigger THIS CoinIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…August 26, 2024 | finance.yahoo.comCODX Aug 2024 2.000 put (CODX240830P00002000)August 21, 2024 | nz.finance.yahoo.comCo-Diagnostics Inc (C97.DU)August 15, 2024 | tmcnet.comCo-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.August 13, 2024 | markets.businessinsider.comHold Rating Maintained for Co-Diagnostics Amidst Revenue Growth and Development ProgressAugust 12, 2024 | finance.yahoo.comCo-Diagnostics Second Quarter 2024 Earnings: Beats ExpectationsSeptember 16, 2024 | Crypto 101 Media (Ad)Trillion Dollar Blockchain Shift Could Trigger THIS CoinIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…August 12, 2024 | msn.comCo-Diagnostics, Inc. (NASDAQ:CODX) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comCo-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | investorplace.comCODX Stock Earnings: Co-Diagnostics Beats EPS, Beats Revenue for Q2 2024August 8, 2024 | prnewswire.comCo-Diagnostics, Inc. Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | markets.businessinsider.comCo-Diagnostics is about to announce its earnings — here's what to expectJuly 29, 2024 | prnewswire.comCo-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in ChicagoJuly 25, 2024 | prnewswire.comCo-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and WebcastJuly 2, 2024 | prnewswire.comCo-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. StatesJune 18, 2024 | prnewswire.comCo-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21See More Headlines Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/16/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:CODX CUSIPN/A CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Potential Upside/Downside+16.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,330,000.00 Net Margins-411.18% Pretax Margin-391.89% Return on Equity-44.69% Return on Assets-40.47% Debt Debt-to-Equity RatioN/A Current Ratio9.09 Quick Ratio8.81 Sales & Book Value Annual Sales$9.14 million Price / Sales4.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.46Miscellaneous Outstanding Shares31,278,000Free Float30,527,000Market Cap$40.35 million OptionableOptionable Beta-0.86 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Dwight H. Egan (Age 71)Chairman & CEO Comp: $415.75kMr. Brian L. Brown CPA (Age 48)CFO & Company Secretary Comp: $338.92kMr. Richard David Abbott (Age 52)President Dr. Brent C. Satterfield Ph.D. (Age 47)Co-Founder & Member of Scientific Advisory Board Comp: $237.5kMr. David NielsenChief Operating OfficerMr. Dan Bohrer CPAVice President of Finance & AccountingMr. Christopher ThurstonChief Technology OfficerDr. Mark Poritz Ph.D.Chief Scientific OfficerMr. Andrew BensonHead of Investor RelationsDr. Mayuranki AlmaulaSenior Vice President of Overseas Operations & Strategic AlliancesMore ExecutivesKey CompetitorsPolyPidNASDAQ:PYPDTriSalus Life SciencesNASDAQ:TLSIElectromedNYSE:ELMDFractyl HealthNASDAQ:GUTSLakeland IndustriesNASDAQ:LAKEView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 13,400 shares on 8/9/2024Ownership: 1.877%Koss Olinger Consulting LLCBought 58,887 shares on 8/6/2024Ownership: 0.188%SMI Advisory Services LLCSold 10,089 shares on 7/15/2024Ownership: 0.090%View All Institutional Transactions CODX Stock Analysis - Frequently Asked Questions How have CODX shares performed this year? Co-Diagnostics' stock was trading at $1.33 at the start of the year. Since then, CODX stock has decreased by 3.0% and is now trading at $1.29. View the best growth stocks for 2024 here. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.09. The firm had revenue of $2.66 million for the quarter, compared to the consensus estimate of $0.40 million. Co-Diagnostics had a negative trailing twelve-month return on equity of 44.69% and a negative net margin of 411.18%. When did Co-Diagnostics IPO? Co-Diagnostics (CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO. Who are Co-Diagnostics' major shareholders? Top institutional shareholders of Co-Diagnostics include Renaissance Technologies LLC (1.88%), Koss Olinger Consulting LLC (0.19%) and SMI Advisory Services LLC (0.09%). View institutional ownership trends. How do I buy shares of Co-Diagnostics? Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and iBio (IBIO). This page (NASDAQ:CODX) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Co-Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
